Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 34 Leukemia 34 Lymphoma, Follicular 27 Melanoma 25 Leukemia, Lymphocytic, Chronic, B-Cell 22 Precursor Cell Lymphoblastic Leukemia-Lymphoma 21 Lymphoma, Non-Hodgkin 20 Leukemia, Myeloid, Acute 20 Multiple Myeloma 18 Breast Neoplasms 18 Lymphoma, Large B-Cell, Diffuse 17 Prostatic Neoplasms 15 Lymphoma, Mantle-Cell 15 Lymphoma, Large-Cell, Immunoblastic 15 Neuroblastoma 14 Neoplasms, Plasma Cell 13 Myelodysplastic Syndromes 13 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13 Hodgkin Disease 13 Burkitt Lymphoma 13 Leukemia, Myeloid, Chronic-Phase 12 Neoplasm Metastasis 11 Lymphoma, B-Cell, Marginal Zone 11 Lung Neoplasms 10 Glioblastoma 9 Carcinoma, Non-Small-Cell Lung 9 Myeloproliferative Disorders 8 Leukemia, Myeloid, Accelerated Phase 8 Ovarian Neoplasms 7 Gliosarcoma 7

Interventions

sargramostim 1 Temozolomide 1 Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Tetanus × sargramostim × Clear all

NCT03927222 2024-04-08

I-ATTAC

Duke University

Phase 2 Terminated

6 enrolled 7 charts

Glioblastoma, Tetanus

Data powered by HemOnc (CC BY 4.0) Colophon ⚡